Back to top

gene-editing: Archive

Zacks Equity Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change SANAPositive Net Change

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

RHHBYPositive Net Change SRPTNegative Net Change PBYINegative Net Change SLDBNegative Net Change

Zacks Equity Research

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPPositive Net Change